详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. [2]Amity School of Pharmaceutical Sciences, Amity University, Mohali, Punjab, India. [3]GHG Khalsa College of Pharmacy, Ludhiana, Punjab, India. [4]Pranveer Singh Institute of Technology, Pharmacy, Kanpur, Uttar Pradesh, India. [5]SMBT College of Pharmacy, Ghoti Kh, Maharashtra, India. [6]School of Pharmaceutical Sciences, Chhatrapati Shahu Ji Maharaj University, Kanpur, Uttar Pradesh, India. [7]Department of Pharmaceutics, College of Pharmacy, Prince Sattam Bin Abdulaziz University, Alkharj, Saudi Arabia. [8]School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India. [9]Australian Research Consortium in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Ultimo, NSW, Australia. [10]Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania. [11]Doctoral School of Biomedical Sciences, University of Oradea, Oradea, Romania.

出处：

DOI：

ISSN：

关键词： neuroblastoma molecular targets immunotherapy precision interventions preclinical studies

摘要：

Neuroblastoma (NB) is the most frequent solid tumor in pediatric cases, contributing to around 15% of childhood cancer-related deaths. The wide-ranging genetic, morphological, and clinical diversity within NB complicates the success of current treatment methods. Acquiring an in-depth understanding of genetic alterations implicated in the development of NB is essential for creating safer and more efficient therapies for this severe condition. Several molecular signatures are being studied as potential targets for developing new treatments for NB patients. In this article, we have examined the molecular factors and genetic irregularities, including those within insulin gene enhancer binding protein 1 (ISL1), dihydropyrimidinase-like 3 (DPYSL3), receptor tyrosine kinase-like orphan receptor 1 (ROR1) and murine double minute 2-tumor protein 53 (MDM2-P53) that play an essential role in the development of NB. A thorough summary of the molecular targeted treatments currently being studied in pre-clinical and clinical trials has been described. Recent studies of immunotherapeutic agents used in NB are also studied in this article. Moreover, we explore potential future directions to discover new targets and treatments to enhance existing therapies and ultimately improve treatment outcomes and survival rates for NB patients.Copyright © 2024 Zheng, Kumar, Sharma, Behl, Sehgal, Wal, Shinde, Kawaduji, Kapoor, Anwer, Gulati, Shen, Singla and Bungau.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 2 区生物学

小类 | 2 区发育生物学 3 区细胞生物学

第一作者：

第一作者机构： [1]Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China.

共同第一作者：

通讯作者：

通讯机构： [1]Joint Laboratory of Artificial Intelligence for Critical Care Medicine, Department of Critical Care Medicine and Institutes for Systems Genetics, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, China. [8]School of Pharmaceutical Sciences, Lovely Professional University, Phagwara, Punjab, India.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Revolutionizing pediatric neuroblastoma treatment: unraveling new molecular targets for precision interventions

文献详情

相关文献